US2018267028A1PendingUtilityA1

Specific Targeting of RNA Expanded Repeat Sequences

Assignee: SCRIPPS RESEARCH INSTPriority: Jul 15, 2013Filed: Mar 8, 2018Published: Sep 20, 2018
Est. expiryJul 15, 2033(~7 yrs left)· nominal 20-yr term from priority
C07D 495/04C07D 403/14C07D 519/00G01N 2500/04A61K 48/00G01N 33/5308G01N 2500/10
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG) exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG) exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein
 each individually selected R or R′ is H or (C1-C6)alkyl; 
 n1 is 2, 3, 4, 5, or 6; 
 Z is a (C1-C3)alkylene group, optionally substituted with a reporter or affinity group; 
 L is a linker group comprising an optionally substituted (C1-C6)alkylene, wherein one or two carbon atoms is optionally replaced by O; 
 XL is an RNA-reactive crosslinking group; 
 each individually selected Ht is a group of formula 
 
       
       
         
           
           
               
               
           
         
         wherein
 n2 is 0, 1, 2, or 3; 
 n3 is 0, 1, 2, or 3; 
 Y is O or CH 2 ; 
 a wavy line indicates a point of bonding; 
 or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
 
       
     
     
         2 . The compound of  claim 1  wherein the crosslinking group is an alkylating group. 
     
     
         3 . The compound of  claim 2  wherein the alkylating group is a chlorambucil derivative. 
     
     
         4 . The compound of  claim 1  wherein the crosslinking group is a triggered crosslinker using photochemical or shape-triggered catalysis. 
     
     
         5 . The compound of  claim 1  wherein the compound is of formula 
       
         
           
           
               
               
           
         
         or is of formula 
       
       
         
           
           
               
               
           
         
         wherein Ht, R, and R′, are as defined in  claim 1 ;
 or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
 
       
     
     
         6 . The compound of  claim 1  wherein Ht is 
       
         
           
           
               
               
           
         
         wherein a wavy line indicates a point of bonding; 
         R is n-propyl; R′ is H; or any combination thereof; 
         or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
       
     
     
         7 . The compound of  claim 1  wherein the compound is 2H-4-CA of formula 
       
         
           
           
               
               
           
         
         or is compound 2H-5-CA of formula 
       
       
         
           
           
               
               
           
         
         wherein Ht is a group of formula 
       
       
         
           
           
               
               
           
         
         wherein a wavy line indicates a point of bonding; 
         or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
       
     
     
         8 . The compound of  claim 1  wherein Z is an unsubstituted alkylene group. 
     
     
         9 . The compound of  claim 1  wherein Z is an alkylene group substituted with an affinity group. 
     
     
         10 . The compound of  claim 9  wherein the affinity group is a biotin-comprising moiety. 
     
     
         11 . The compound of  claim 10 , wherein the compound is 
       
         
           
           
               
               
           
         
         wherein Ht, R, R′, n1, L, and XL, are as defined in  claim 1 ; 
         or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
       
     
     
         12 . The compound of  claim 11 , wherein n1 is 4 or 5. 
     
     
         13 . The compound of  claim 12 , wherein the compound is 2H-4-CA-biotin of formula 
       
         
           
           
               
               
           
         
         or is 2H-5-CA-biotin of formula 
       
       
         
           
           
               
               
           
         
         or any tautomer thereof; or any salt thereof, or any stereoisomer thereof. 
       
     
     
         14 . A covalently-linked complex of the compound of formula (I) of  claim 1  and a segment of RNA comprising a hairpin loop. 
     
     
         15 . The complex of  claim 14  wherein the RNA comprises an r(CUG) exp  segment. 
     
     
         16 . The complex of  claim 14  wherein the RNA comprises an r(CGG) exp  segment.

Join the waitlist — get patent alerts

Track US2018267028A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.